Analyses of Interleukin-6, Presepsin and Pentraxin-3 in the Diagnosis and Severity of Late-onset Preeclampsia
Analyses of Interleukin-6, Presepsin and Pentraxin-3 in the Diagnosis and Severity of Late-onset Preeclampsia
Introduction: The etiology/pathophysiology of preeclampsia remains an enigma. Cellular
 immunity is a key factor in the etiology of late-onset preeclampsia (L-PrE). Presepsin is
 split out from the phagocytes membranes after phagocytosis. To investigators knowledge, this
 is the first study in literature to investigate maternal blood concentrations of presepsin in
 preeclampsia and healthy pregnant women.

 Methods: The investigators examined maternal plasma interleukin-6, presepsin and pentraxin-3
 concentrations in pregnant women with (n=44) and without L-PrE (n=44). These three
 inflammatory markers concentrations measured using enzyme-linked immunosorbent assays were
 compared.
This observational case-control study was designed at Cengiz Gokcek Women's and Children's
 Hospital, Gaziantep, Turkey, in the Department of Obstetrics and Gynecology between June 2018
 and January 2019. The protocol was approved by the Ethics Committee for Clinical Research of
 Gaziantep University (Reference number: 2018/393). The study strictly adhered to the
 principles of the Declaration of Helsinki. All subjects included in the study gave oral and
 written informed consent. Eighty-eight women were enrolled in the study in two groups. All
 participants will gave their oral and written informed consent before their inclusion in the
 study.
Inclusion Criteria:

 -  preeclampsia healthy pregnancy

 Exclusion Criteria:

 1. pregnant women with any systemic condition (such as chronic hypertension, inflammatory
 and rheumatic diseases),

 2. using any kind of medication throughout pregnancy (such as acetylsalicylic acid,
 corticosteroids or heparin),

 3. pregnant women who had fever at the time of the first admission,

 4. concurrent infections (urinary tract infection, cervicitis, etc.),

 5. pregnancies complicated with premature membrane rupture or chorioamnionitis,

 6. history of medication for PE treatment at the time of the first admission,

 7. patients who had fetal congenital abnormalities or genetic syndromes,

 8. drug user,

 9. multiple gestations,

 10. active labor.